Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics (DE:2LB)
:2LB
2LB Stock Chart & Stats
Day’s Range― - ―
52-Week Range€5.05 - €16.85
Previous CloseN/A
Volume0.00
Average Volume (3M)665.00
Market Cap
€1.67B
Enterprise Value€2.53B
Total Cash (Recent Filing)$82.15M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Feb 27, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding304,780,800
10 Day Avg. Volume232
30 Day Avg. Volume665
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)19.39
Price to Cash Flow (P/CF)-7.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-264.39
Enterprise Value/Ebitda-6.38
Forecast
1Y Price Target
€18.54Price Target Upside263.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Financial Performance3Q24 financial results were higher than consensus revenue estimates, indicating strong financial performance.
Revenue GuidanceManagement reiterated 2025 revenue guidance of $450-475MM, which will be driven by continued expansion within ATCs.
Bears Say
Revenue MissQ4 Amtagvi revenue of $49MM missed consensus of $55MM by 11%.
---
Options Prices
Currently, No data available
---
Ownership Overview
9.64% Insiders
17.91% Mutual Funds
35.62% Other Institutional Investors
19.91% Public Companies and Individual Investors
2LB FAQ
What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was €5.05 and its highest was €16.85 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is €1.67B.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s upcoming earnings report date is Feb 27, 2025 which is 2 days ago.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on Feb 27, 2025. The company reported -€0.25 earnings per share for the quarter, beating the consensus estimate of -€0.258 by €0.008.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics does not currently pay dividends.
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate is -0.25.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 304,780,800 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -€0.25 in its last earnings report, beating expectations of -€0.258. Following the earnings report the stock price went down -20.973%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Currently, no hedge funds are holding shares in DE:2LB
---
Iovance Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€18.54 (263.46% Upside)
€18.54 (263.46% Upside)
Blogger Sentiment
Bullish
DE:2LB Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $503.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.89%
12-Months-Change
Fundamentals
Return on Equity
-56.65%
Trailing 12-Months
Asset Growth
16.29%
Trailing 12-Months
Company Description
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
---
2LB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant revenue growth, successful commercial adoption of Amtagvi, and positive clinical trial results. Despite net losses and initial challenges in ATC performance, the overall sentiment is positive due to surpassing revenue expectations and a solid financial outlook.Read More>---
2LB Stock 12 Month Forecast
Average Price Target
€18.54
▲(263.46% Upside)
Technical Analysis
Best Analysts Covering 2LB
1 Year
1 Year Success Rate
9/29 ratings generated profit
1 Year Average Return
-4.45%
reiterated a buy rating yesterday
Copying Reni Benjamin's trades and holding each position for 1 Year would result in 31.03% of your transactions generating a profit, with an average return of -4.45% per trade.
---